A report released on July 25, 2012 by staff in the US Senate committee on Commerce, Science and Transportation, examined the gray market for prescription drugs and why hospitals are forced to pay extremely high prices for some drugs. One example focuses on the drug Fluorouracil, a chemotherapy drug that was sold to a pharmacy by the distributor, resold into the gray market and made its way through several distributors, each adding its own markup, until the retail markup was 8471 %. In the presence of supply shortages, hospitals are forced to pay such prices. Most of these drugs are generic with few producers given the low margins during earlier years. Given that supply shortages will generate such creative supply chains, what should the US government do to assist ? Will margin guarantees incent manufacturers to maintain capacity ? Should distributors be barred from reselling to other distributors ? Or should margins be regulated ?